FDA: Page 2
Cindy Whitehead spent years working on a treatment for low sexual desire in women. When the FDA rejected her drug, she disputed the decision with the stories of affected women -- and won.
The drug, which contains a tiny ingestible sensor, is designed for patients with mental illness.
David Acheson, a former official at the U.S. Food and Drug Administration and the U.S. Department of Agriculture, was brought on as an adviser.
But don't worry, barely any of the food was affected, company spokesperson says.
The agency will look into whether the ads obscure important safety and side effect information.
Through education, proactive self-regulation and collaboration with regulators, industry leaders can help speed the process of rule-making.
'Lumosity simply did not have the science to back up its ads,' said the FTC's director of consumer protection.
Although the polarizing product likely won't come to market for years, it's already making waves.
The investigations follow complaints filed by two former Theranos employees, casting even greater doubt upon the honesty and accuracy of the $9 billion blood test startup.
Get inspired by these recent wins for the entrepreneurial community.
The news comes just four months after Valeant Pharmaceuticals acquired Sprout for $1 billion.
Six years after New York City's mandate that calories be listed at chain restaurants, researchers have found that these labels, on their own, do not reduce the overall number of calories ordered.
The startup responded to the agency's demand it stops claiming it makes mayonnaise.
The startup can now market direct-to-consumer genetic tests that include carrier status, wellness trait and ancestry reports.